Cargando…

Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials

RATIONALE & OBJECTIVE: In FIDELITY, finerenone improved cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). This analysis explored the efficacy and safety of finerenone in Black patients. STUDY DESIGN: Subanalysis of randomized controlled trials. SETTING...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flack, John M., Agarwal, Rajiv, Anker, Stefan D., Pitt, Bertram, Ruilope, Luis M., Rossing, Peter, Adler, Sharon G., Fried, Linda, Jamerson, Kenneth, Toto, Robert, Brinker, Meike, Farjat, Alfredo E., Kolkhof, Peter, Lawatscheck, Robert, Joseph, Amer, Bakris, George L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692708/ https://www.ncbi.nlm.nih.gov/pubmed/38046911 http://dx.doi.org/10.1016/j.xkme.2023.100730

Ejemplares similares

Generalizability of FIGARO‐DKD and FIDELIO‐DKD Trial Criteria to the US Population Eligible for Finerenone
por: Chiu, Nicholas, et al.
Publicado: (2022)

Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study
por: Ruilope, Luis M, et al.
Publicado: (2022)

Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial
por: Filippatos, Gerasimos, et al.
Publicado: (2021)

Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results
por: Agarwal, Rajiv, et al.
Publicado: (2021)

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA(1c) and Insulin Use: An Analysis From the FIDELIO-DKD Study
por: Rossing, Peter, et al.
Publicado: (2022)

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial
por: Rossing, Peter, et al.
Publicado: (2021)

Dose–Exposure–Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD
por: Goulooze, Sebastiaan Camiel, et al.
Publicado: (2022)

Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria
por: Goulooze, Sebastiaan Camiel, et al.
Publicado: (2021)

Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis
por: van den Berg, Paul, et al.
Publicado: (2021)

Update on Diabetic Kidney Disease (DKD): Focus on Non-Albuminuric DKD and Cardiovascular Risk
por: Scilletta, Sabrina, et al.
Publicado: (2023)

The FIDELIO Study Podcast
por: Toto, Robert, et al.
Publicado: (2022)

Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis
por: Rosas, Sylvia E., et al.
Publicado: (2023)

Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems
por: Kolkhof, Peter, et al.
Publicado: (2022)

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2020)

Correction to: The FIDELIO Study Podcast
por: Toto, Robert, et al.
Publicado: (2022)

Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone
por: Agarwal, Rajiv, et al.
Publicado: (2020)

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
por: Agarwal, Rajiv, et al.
Publicado: (2021)

Detection of DKD stage 1 and treatment are essential
por: Futrakul, Narisa, et al.
Publicado: (2018)

Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

The role of lncRNAs in regulation of DKD and diabetes-related cancer
por: Cheng, Yawei, et al.
Publicado: (2022)

Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis
por: Pitt, Bertram, et al.
Publicado: (2022)

Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon‐like peptide‐1 receptor agonist use
por: Rossing, Peter, et al.
Publicado: (2022)

Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
por: Rossing, Peter, et al.
Publicado: (2021)

Role of Sphingolipid Signaling in Glomerular Diseases: Focus on DKD and FSGS
por: Mitrofanova, Alla, et al.
Publicado: (2020)

2DKD: a toolkit for content-based local image search
por: DeVille, Julian S., et al.
Publicado: (2020)

Virtual Patient Simulation in DKD: Successful Strategy for Improving Recognition and Management
por: Larkin, Amy, et al.
Publicado: (2021)

Network Pharmacology-Based Prediction of Mechanism of Shenzhuo Formula for Application to DKD
por: Wang, Xinmiao, et al.
Publicado: (2021)

A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease
por: Agarwal, Rajiv, et al.
Publicado: (2022)

Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes
por: Ruilope, Luis M., et al.
Publicado: (2022)

Lessons learned from two randomized controlled trials: CITIES and STOP-DKD
por: Zullig, Leah L., et al.
Publicado: (2020)

ODP223 Metabolic efficacy of Very Low Carbohydrate Diet in DKD patients
por: Zainordin, Nur Aisyah, et al.
Publicado: (2022)

Both sexes develop DKD in the CD1 uninephrectomized streptozotocin mouse model
por: Trink, Jackie, et al.
Publicado: (2023)

Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model
por: Willis, Michael, et al.
Publicado: (2020)

The 2021–2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKD
por: de Sá, João Roberto, et al.
Publicado: (2022)

The Saudi Diabetic Kidney Disease study (Saudi-DKD): clinical characteristics and biochemical parameters
por: Al-Rubeaan, Khalid, et al.
Publicado: (2018)

Non-Albumin Proteinuria (NAP) as a Complementary Marker for Diabetic Kidney Disease (DKD)
por: Bae, Jaehyun, et al.
Publicado: (2021)

Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis
por: Filippatos, Gerasimos, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rlgm8f3fbmbgal04qlaehkdi2q